Article
Cancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinoma.
Science (New York, N.Y.) - 12 Mar 2026
Than Minh T, Dequiedt Lucie, Sor Rina, Nair Shreya, Markosyan Nune, Furth Emma E, Yang Chenghua, Ray-Fofana Courtney, Menard Marie, Quintana Elsa, Edwards A Cole, Hennessey Connor J, Good Austin L, Quinones Liz, Hwang Yunseo, Clendenin Cynthia, Kiemen Ashley L, Vonderheide Robert H, Stanger Ben Z
Abstract excerpt
Transformation of pancreatic epithelial cells to malignant pancreatic ductal adenocarcinoma (PDAC) typically involves the progression of precancerous pancreatic intraepithelial neoplasia (PanINs) bearing oncogenic KRAS mutations. Here, we tested the impact of PDAC interception using either RAS(ON) multiselective or RAS(ON) G12D-selective pharmacological inhibitors [RAS(ON) inhibitors] in mouse models of PDAC....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.